Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ALT NASDAQ:GERN NASDAQ:KALA NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.91+0.6%$3.34$1.07▼$4.08$1.03B0.884.21 million shs956,497 shsALTAltimmune$4.21+0.6%$5.58$2.90▼$11.16$341.80M0.473.36 million shs1.35 million shsGERNGeron$1.30+2.8%$1.43$1.17▼$5.06$824.81M0.6411.22 million shs2.83 million shsKALAKALA BIO$6.12+11.6%$4.36$2.92▼$11.20$39.45M-1.8849,658 shs84,182 shsVRNAVerona Pharma PLC American Depositary Share$104.770.0%$85.24$18.51▼$104.99$8.49B0.241.70 million shs5.24 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-2.27%+4.58%+8.99%+104.21%+196.18%ALTAltimmune-1.88%-8.73%-39.60%-5.00%-47.09%GERNGeron-5.97%-9.35%-16.56%+1.61%-74.29%KALAKALA BIO-4.04%+6.01%+27.21%+57.64%-28.12%VRNAVerona Pharma PLC American Depositary Share+0.10%+20.62%+13.63%+79.71%+387.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics3.6543 of 5 stars3.61.00.04.02.10.80.6ALTAltimmune2.1879 of 5 stars3.41.00.00.03.21.70.6GERNGeron3.4153 of 5 stars3.32.00.01.32.71.70.6KALAKALA BIO3.8826 of 5 stars3.52.00.04.42.30.80.6VRNAVerona Pharma PLC American Depositary Share2.2695 of 5 stars2.15.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7572.86% UpsideALTAltimmune 2.75Moderate Buy$18.20332.82% UpsideGERNGeron 2.60Moderate Buy$4.61256.07% UpsideKALAKALA BIO 3.00Buy$13.00112.59% UpsideVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.004.04% UpsideCurrent Analyst Ratings BreakdownLatest ALT, VRNA, AKBA, GERN, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $15.007/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$1.007/10/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.007/10/2025VRNAVerona Pharma PLC American Depositary ShareBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/9/2025VRNAVerona Pharma PLC American Depositary ShareCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M6.40N/AN/A($0.23) per share-16.98ALTAltimmune$20K17,053.38N/AN/A$1.74 per share2.42GERNGeron$76.99M10.71N/AN/A$0.46 per share2.82KALAKALA BION/AN/AN/AN/A$2.02 per shareN/AVRNAVerona Pharma PLC American Depositary Share$118.54M71.66N/AN/A$2.56 per share40.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)GERNGeron-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)KALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,492.17N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest ALT, VRNA, AKBA, GERN, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ALTAltimmune-$0.3006N/AN/AN/AN/AN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A8/5/2025Q2 2025KALAKALA BIO-$1.82N/AN/AN/AN/AN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.892.232.02ALTAltimmuneN/A15.8515.85GERNGeron0.447.876.97KALAKALA BIO3.191.991.99VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALTAltimmune78.05%GERNGeron73.71%KALAKALA BIO24.61%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ALTAltimmune4.10%GERNGeron7.42%KALAKALA BIO8.32%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million254.76 millionOptionableALTAltimmune5081.11 million77.78 millionOptionableGERNGeron70636.92 million589.66 millionOptionableKALAKALA BIO306.45 million5.92 millionNot OptionableVRNAVerona Pharma PLC American Depositary Share3081.08 million81.05 millionOptionableALT, VRNA, AKBA, GERN, and KALA HeadlinesRecent News About These CompaniesWeathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now2 hours ago | zacks.comJacobson & Schmitt Advisors LLC Lowers Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)3 hours ago | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Neutral" Rating at HC WainwrightJuly 16 at 3:01 AM | americanbankingnews.comHC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 15 at 11:46 PM | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15 at 11:46 PM | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15 at 1:01 PM | zacks.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)July 14 at 7:07 PM | globenewswire.comPharmaceutical Stocks To Research - July 14thJuly 14 at 2:47 PM | marketbeat.comTimesSquare Capital Management LLC Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14 at 8:50 AM | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14 at 8:45 AM | marketbeat.comRice Hall James & Associates LLC Has $52.25 Million Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14 at 6:34 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at BTIG ResearchJuly 13 at 2:35 AM | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to Hold at Roth CapitalJuly 13 at 2:35 AM | americanbankingnews.comVERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNAJuly 12, 2025 | businesswire.comBTIG Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 12, 2025 | msn.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at Wolfe ResearchJuly 12, 2025 | marketbeat.comDiversify Wealth Management LLC Acquires 3,572 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 12, 2025 | marketbeat.comAlps Advisors Inc. Sells 5,993 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 12, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Rating Lowered to Hold at Wells Fargo & CompanyJuly 12, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Rating Lowered by TD CowenJuly 12, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share's (VRNA) Hold Rating Reiterated at Jefferies Financial GroupJuly 12, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeDo They Know Something? Insiders & Congress Buy UnitedHealthBy Brian O'Connell | July 9, 2025View Do They Know Something? Insiders & Congress Buy UnitedHealthForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffTop 3 Silver Picks to Watch as Bull Market Gains SteamBy Chris Markoch | June 18, 2025View Top 3 Silver Picks to Watch as Bull Market Gains SteamWhy Realty Income’s 5.59% Yield Makes It a Must-Buy REITBy Jeffrey Neal Johnson | July 2, 2025View Why Realty Income’s 5.59% Yield Makes It a Must-Buy REITALT, VRNA, AKBA, GERN, and KALA Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.90 +0.03 (+0.64%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Altimmune NASDAQ:ALT$4.22 +0.03 (+0.84%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Geron NASDAQ:GERN$1.30 +0.04 (+2.78%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.KALA BIO NASDAQ:KALA$6.12 +0.64 (+11.59%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$104.76 -0.01 (0.00%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
